Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition containing alkalizer and eltrombopag and use thereof

A technology of a composition and an alkalizing agent, applied in the field of biomedicine, can solve problems such as the need for further research

Active Publication Date: 2022-04-29
SUNSHINE LAKE PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, at this stage, the research on Eltrombopag drug needs to be deepened.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing alkalizer and eltrombopag and use thereof
  • Pharmaceutical composition containing alkalizer and eltrombopag and use thereof
  • Pharmaceutical composition containing alkalizer and eltrombopag and use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0036] The preparation of pharmaceutical composition tablets: including but not limited to powder direct compression method and wet granulation tabletting method: the powder direct compression method is specifically, weighing each component respectively, mixing each component uniformly and directly compressing the tablet to obtain Drug combination tablet for in vitro dissolution test; the wet granulation and tabletting method specifically includes weighing each component separately, mixing some components first, adding purified water or an aqueous solution containing an alkalizing agent, wet granulation, drying, and sizing , and then add the remaining external ingredients such as magnesium stearate, etc., mix and compress into tablets to obtain drug combination tablets for in vitro dissolution tests;

[0037] Preparation of drug capsules: including but not limited to powder method and wet granulation method: the powder method is specifically, weighing a certain amount of eltrom...

Embodiment 1

[0040] In this example, HPLC tests were performed on a series of stock solutions of the test article in different media. In this example, 0.1mol / L HCl, pH 2.0, pH 3.0, pH 4.0, pH 4.5, pH 5.0, pH 6.0, pH 6.8, pH 7.5 and purified water were used for comparison. The equilibrium solubility of Eltrombopag in different media of this embodiment is shown in the table below:

[0041] medium Solubility (μg / ml) 0.1mol / L HCl 0.00 pH 2.0 0.00 pH 3.0 0.00 pH 4.0 0.00 pH 4.5 0.00 pH 5.0 0.00 pH 6.0 0.44 pH 6.8 2.64 pH 7.5 8.78 purified water 1485.23

[0042] It can be seen from the above table that Eltrombopag has the highest solubility in purified water, while other media have lower solubility. The solubility of Eltrombopag in the medium will affect the dissolution effect. If the solubility is too small, it is difficult to distinguish the difference in the dissolution of the pharmaceutical composition. Therefore, i...

Embodiment 2

[0054] In this example, according to the test conditions substantially the same as in Comparative Example 2, the pharmaceutical composition tablet was dissolved in purified water and an aqueous solution containing 2.78mmol / L calcium chloride for HPLC testing. The difference is that in this embodiment, the content of three specific components of the pharmaceutical composition changes: 16.10% by weight of mannitol, 35.50% by weight of microcrystalline cellulose, and 7.50% by weight of newly added sodium carbonate. And, this embodiment is the wet granulation tabletting method: Eltrombopag, mannitol, microcrystalline cellulose, sodium carboxymethyl starch and povidone were first mixed for 10 minutes, and then an aqueous solution of sodium carbonate was added to granulate, Pass the wet granules through a 30-mesh sieve, dry the dry granules in an oven at 50 degrees Celsius for 2 hours, pass through a 30-mesh sieve, add magnesium stearate and mix for 5 minutes, and finally compress to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention proposes a pharmaceutical composition containing an alkalizing agent and Eltrombopag and its use. The pharmaceutical composition contains: Eltrombopag or a pharmaceutically acceptable salt thereof; and an alkalizing agent, the alkalizing agent At least one selected from monovalent metal weak acid salts and monovalent metal hydroxides is included. The pharmaceutical composition proposed by the present invention can improve the dissolution rate of the drug, and is beneficial to the absorption of the Eltrombopag drug. Even if it is taken with food, it can achieve a similar effect to that of taking it on an empty stomach, thereby reducing the overdose of Eltrombopag medication. More restrictions can increase the flexibility and compliance of patients in taking medicine, and at the same time, it can also avoid the reduction or even ineffectiveness of the curative effect caused by improper taking of medicine, so as to ensure the normal play of the medicine effect.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular, the invention relates to a pharmaceutical composition containing an alkalizing agent and Eltrombopag and its application. Background technique [0002] Eltrombopag is used for the treatment of thrombocytopenia in patients with chronic idiopathic thrombocytopenic purpura (ITP) after glucocorticoids, immunoglobulin therapy or splenectomy, and in patients with chronic hepatitis C Symptoms such as hypopenias and severe aplastic anemia that do not respond adequately to immunosuppressive therapy. [0003] Eltrombopag is taken once a day, and it must be taken orally on an empty stomach, that is, it must be taken 1 hour before or 2 hours after meals, and it must not be taken before or after 4 hours of taking the medicine containing polyvalent metal ions (such as: Iron ions, calcium ions, zinc ions, magnesium ions), such as antacids, calcium ion-rich products, and mineral supplements. Therefore...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4152A61K47/02A61K9/20A61K9/48A61K9/16A61P7/04A61P7/06
CPCA61K47/02A61K9/1611A61K9/2004A61K9/2095A61K9/485A61K31/4152
Inventor 石添香黄心游劲松黄芳芳
Owner SUNSHINE LAKE PHARM CO LTD